SUNNYVALE, Calif., April 28 /PRNewswire-FirstCall/ --
Scios Inc. (Nasdaq: SCIO) today announced that its stockholders have voted to
approve the merger agreement pursuant to which Scios is being acquired by
Johnson & Johnson. The closing of the transaction is expected to occur within
the next few days.
Scios Inc.
Scios is a biopharmaceutical company developing novel treatments for
cardiovascular and inflammatory diseases. The company's disease-based
technology platform integrates expertise in protein biology with computational
and medicinal chemistry to identify novel targets and rationally design small
molecule compounds for large markets with unmet medical needs.
Forward-Looking Safe Harbor Statement
This news release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, which may include statements concerning the proposed
acquisition by Johnson & Johnson and strategic plans, expectations, and
objectives for future operations. We generally identify such forward-looking
statements using words like "estimate," "believe," "intend," "expect," "may,"
"should," "plan," "project," "contemplate," "anticipate" or similar
statements. Statements that are not historical facts are forward-looking
statements based on current assumptions that involve risks and uncertainties.
These risks and uncertainties may include the sales penetration and success of
Natrecor, the success of clinical trials of Natrecor and our pipeline
products, the failure to complete the proposed transaction in a timely manner,
actions of governmental entities, and costs related to the merger, as well as
other risks detailed from time to time in the reports filed by Scios with the
SEC, including the Company's quarterly reports and annual report on Form 10-K.
Actual results, performance or achievements of Scios may differ significantly
from those described in these forward-looking statements. Scios disclaims any
intention or obligation to update or revise any financial projections or
forward-looking statements, whether as a result of new information, future
events or otherwise.
SOURCE Scios Inc.
 back to top
Related links:
http://www.sciosinc.com
CONTACT:
media and investors, Suzanne Beveridge of
Scios Inc., +1-408-616 2947; or, media, Jim Weiss of WeissCom
Partners, Inc., +1-415-260-1274, for Scios Inc.
|
